Abstract: The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation.
Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Grant
Filed:
August 22, 2018
Date of Patent:
March 17, 2020
Assignees:
RHIZEN PHARMACEUTICALS SA, INCOZEN THERAPEUTICS PVT. LTD.
Inventors:
Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Grant
Filed:
March 9, 2017
Date of Patent:
October 2, 2018
Assignees:
INCOZEN THERAPEUTICS PVT. LTD., RHIZEN PHARMACEUTICALS SA
Inventors:
Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
Type:
Grant
Filed:
February 4, 2014
Date of Patent:
September 12, 2017
Assignees:
INCOZEN THERAPEUTICS PVT. LTD., RHIZEN PHARMACEUTICALS SA
Inventors:
Meyyappan Muthuppalaniappan, Prashant K. Bhavar, Srikant Viswanadha, Swaroop K. Vakkalanka, Gayatri S. Merikapudi
Abstract: The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation.
Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
December 16, 2014
Assignees:
Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
Inventors:
Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
Type:
Application
Filed:
February 4, 2014
Publication date:
August 7, 2014
Applicants:
Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals SA
Abstract: The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation.
Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Application
Filed:
May 10, 2013
Publication date:
October 3, 2013
Applicants:
Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Grant
Filed:
May 16, 2011
Date of Patent:
July 9, 2013
Assignees:
Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals SA
Inventors:
Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Application
Filed:
November 9, 2011
Publication date:
March 8, 2012
Applicants:
Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals SA
Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Application
Filed:
May 16, 2011
Publication date:
November 17, 2011
Applicants:
Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
Type:
Application
Filed:
May 5, 2011
Publication date:
November 10, 2011
Applicants:
Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
Inventors:
Meyyappan MUTHUPPALANIAPPAN, Prashant K. BHAVAR, Srikant VISWANADHA, Swaroop Kumar V.S. VAKKALANKA, Gayatri S. MERIKAPUDI
Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Application
Filed:
November 3, 2010
Publication date:
May 19, 2011
Applicants:
Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
Type:
Application
Filed:
October 6, 2010
Publication date:
May 12, 2011
Applicants:
Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals SA
Inventors:
MEYYAPPAN MUTHUPPALANIAPPAN, Srikant Viswanadha, Kanthikiran V. Varanasi, Gayatri S. Merikapudi, Swaroop Kumar V.S. Vakkalanka
Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
Type:
Application
Filed:
October 6, 2010
Publication date:
May 5, 2011
Applicants:
Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals SA